B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia

  title={B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia},
  author={Maithri Siriwardena and Torsten Kleffmann and Peter N. Ruygrok and Vicky A Cameron and Timothy G. Yandle and Michael Gary Nicholls and Arthur Mark Richards and Christopher J. Pemberton},
Background— The diagnosis of cardiac necrosis such as myocardial infarction can be difficult and relies on the use of circulating protein markers like troponin. However, there is a clear need to identify circulating, specific biomarkers that can detect cardiac ischemia without necrosis. Methods and Results— Using specific immunoassay and tandem mass spectrometry, we show that a fragment derived from the signal peptide of B-type natriuretic peptide (BNPsp) not only is detectable in cytosolic… 

Figures and Tables from this paper

First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers.
ANPsp is a novel circulating natriuretic peptide with potential to act as a cardiovascular biomarker and the rapid increase of plasma ANPsp in STEMI and its significant relationship with blood pressure encourage further study of its potential clinical utility.
Letter by Kavsak et al regarding article, "B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia".
Findings that BNPsp levels are increased in those with ST-segment elevation myocardial infarction are important for their thesis that this peptide may possibly serve as an early biomarker of cardiac ischemia.
B-type natriuretic peptide: from posttranslational processing to clinical measurement.
  • J. Goetze
  • Biology, Medicine
    Clinical chemistry
  • 2012
An ongoing characterization of the molecular heterogeneity may not only help to appreciate the biosynthetic capacity of the endocrine heart but may also lead to the discovery of new and more disease-specific targets for future molecular diagnosis.
Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing.
B-type natriuretic peptides: Looking to the future
It is predicted that circulating levels of these peptides will find increasing diagnostic utility in patients presenting with dyspnoea, in guiding the complex pharmacotherapy in heart failure, and may likewise be useful in guides the management of patients on chronic maintenance renal dialysis.
The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors
The molar ratio of NT-proBNP/BNP may be a significant prognostic factor for HF-related events and is investigated in stable outpatients with cardiovascular risk factors.
B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues.
Release of tissue-specific proteins into coronary perfusate as a model for biomarker discovery in myocardial ischemia/reperfusion injury.
These studies indicate that animal modeling of biomarker release using ex vivo buffer perfused tissue to limit the presence of obfuscating plasma proteins may identify candidates for further study in humans.


Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction.
Natriuretic peptide levels reached their peak around 24 h, later than peak TnT, CK-MB and myoglobin, and NT-BNP and ANP remained elevated on average for 12 weeks, with sustained elevation of these peptides at 12 weeks.
Cardiac natriuretic peptides for cardiac health.
Measurement of BNP/NT-BNP shows particular promise as a 'rule out' test for suspected cases of HF (heart failure) in both emergency care and outpatient settings, and may assist in identifying individuals with asymptomatic ventricular impairment who will benefit from therapy preventing progression to overt HF.
Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide.
IL-6, MCP-1, and NT-proBNP are independent predictors of long-term risk of death or HF, highlighting the importance of identifying leukocyte activation and recruitment in ACS patients.
Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study
Adding cTnT to traditional risk factors improved risk prediction parameters; the improvements were similar to those with N-terminal pro–B-type natriuretic peptide and better than those with the addition of high-sensitivity C-reactive protein.
Ovine brain natriuretic peptide in cardiac tissues and plasma: effects of cardiac hypertrophy and heart failure on tissue concentration and molecular forms.
Findings show that BNP is stored as the prohormone in sheep cardiac tissues and that complete processing to mature forms occurs at the time of secretion, and that the capacity to process the proHormone at secretion is not impaired by chronic heart failure.
Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.
Results indicate that BNP is a novel cardiac hormone secreted predominantly from the ventricle, and that the synthesis, secretion and clearance of BNP differ from those of ANP, suggesting discrete physiological and pathophysiological roles of HBNP in a dual natriuretic peptide system.
Letter by Goetze et al regarding article, "B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia".
The findings challenge the prevailing concepts of peptide biosynthesis and secretion and imply that other regulatory peptide precursors should be reexamined because signal peptide fragments have not been considered of relevance in circulation.
High-Sensitivity Troponin T Concentrations in Acute Chest Pain Patients Evaluated With Cardiac Computed Tomography
Elevation of hsTnT identifies patients with myocardial injury and significant structural heart disease, irrespective of the diagnosis of ACS, among low- to intermediate-risk patients with chest pain, and provides good sensitivity and specificity for ACS.
Multimarker Approach for the Prediction of Heart Failure Incidence in the Community
B-type natriuretic peptide and urinary albumin-to-creatinine ratio emerged as key risk factors for new-onset HF with incremental predictive utility over standard risk factors and were independently associated with nonischemic HF risk.
Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma.
Plasma immunoreactive ANP is responsive to sodium loading in normal man and is elevated in patients with hypervolemic disorders, indicating that the heart secretes alpha hANP or a closely similar peptide which is also present in peripheral venous plasma.